BRPI0606455A - compostos farmacêuticos - Google Patents

compostos farmacêuticos

Info

Publication number
BRPI0606455A
BRPI0606455A BRPI0606455-8A BRPI0606455A BRPI0606455A BR PI0606455 A BRPI0606455 A BR PI0606455A BR PI0606455 A BRPI0606455 A BR PI0606455A BR PI0606455 A BRPI0606455 A BR PI0606455A
Authority
BR
Brazil
Prior art keywords
hydrogen
alkoxy
halogen
carbocyclic
optionally substituted
Prior art date
Application number
BRPI0606455-8A
Other languages
English (en)
Inventor
Neil Thomas Thompson
Jayne Elizabeth Curry
John Francis Lyons
Matthew Simon Squires
Kyla Merriom Thompson
Paul Graham Wyatt
Original Assignee
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astex Therapeutics Ltd filed Critical Astex Therapeutics Ltd
Publication of BRPI0606455A publication Critical patent/BRPI0606455A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSTOS FARMACêUTICOS A invenção fornece uma combinação de agente auxiliar e um composto tendo a fórmula (0): ou sais ou tautómeros ou N-óxidos ou solvatos dos mesmos; em que o agente auxiliar é selecionado a partir de: um anticorpo monoclonal, um agente de alquilação, um agente anticâncer, um outro inibidor de CDK e um hormónio, agonista de hormónio, antagonista de hormónio ou agente de modulação de hormónio; x é um grupo R¹-A-NR¬4¬- ou anel heterocíclico ou carbocíclico de 5 ou 6 membros; A é uma ligação, SO~2~, C=O, NR¬g¬(C=O) ou O(C=O), em que R¬g¬ é hidrogênio ou C~1-4~ hidrocarbila opcionalmente substituída por hidróxi ou C~1-4~ alcóxi; Y é uma ligação ou uma cadeia de alquileno de 1, 2 ou 3 átomos de carbono em comprimento; R¹ é hidrogênio; um grupo carbocíclico ou heterocíclico tendo de 3 a 12 membros de anel; ou um grupo de C~1-8~ hidrocarbila opcionalmente substituída por um ou mais substituintes selecionados a partir de halogênio (por exemplo, flúor), hidróxi, C~1-4~ hidrocarbilóxi, amino, mono- ou di-C~1-4~ hidrocarbilamino, e grupos carbocíclicos ou heterocíclicos tendo de 3 a 12 membros de anel, e, em que 1 ou 2 dos átomos de carbono do grupo de hidrocarbila pode(m) opcionalmente ser substituído(s) por um átomo ou grupo selecionado a partir de O, S, NH, SO, SO~2~; R² é hidrogênio; halogênio; C~1-4~ alcóxi (por exemplo, metóxi); ou um grupo de C~1-4~ hidrocarbila opcionalmente substituída por halogênio (por exemplo, flúor), hidroxila ou C~1-4~ alcóxi (por exemplo, metóxi); R³ é selecionado a partir de hidrogênio e grupos carbocíclicos e heterocíclicos tendo de 3 a 12 membros de anel; e R¬4¬ é hidrogênio ou um grupo de C~1-4~ hidrocarbila opcionalmente substituída por halogênio (por exemplo, flúor), hidroxila ou C~1-4~ alcóxi (por exemplo, metóxi).
BRPI0606455-8A 2005-01-21 2006-01-20 compostos farmacêuticos BRPI0606455A (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US64598805P 2005-01-21 2005-01-21
US64621605P 2005-01-21 2005-01-21
US64597405P 2005-01-21 2005-01-21
US64600105P 2005-01-21 2005-01-21
US64600305P 2005-01-21 2005-01-21
PCT/GB2006/000210 WO2006077428A1 (en) 2005-01-21 2006-01-20 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
BRPI0606455A true BRPI0606455A (pt) 2008-03-11

Family

ID=35967000

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606455-8A BRPI0606455A (pt) 2005-01-21 2006-01-20 compostos farmacêuticos

Country Status (10)

Country Link
US (1) US20090036435A1 (pt)
EP (1) EP1845973B1 (pt)
JP (1) JP5475235B2 (pt)
KR (1) KR101346886B1 (pt)
AU (1) AU2006207325B2 (pt)
BR (1) BRPI0606455A (pt)
CA (1) CA2594477C (pt)
ES (1) ES2552338T3 (pt)
MX (1) MX2007008781A (pt)
WO (1) WO2006077428A1 (pt)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004261459B2 (en) 2003-07-22 2008-06-26 Astex Therapeutics Limited 3, 4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
TW200533657A (en) 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
AR052559A1 (es) * 2005-01-21 2007-03-21 Astex Therapeutics Ltd Derivados de pirazol para inhibir cdk's y gsk's
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US20080139620A1 (en) * 2005-01-21 2008-06-12 Astex Therapeutics Limited Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's
KR101345002B1 (ko) * 2005-01-21 2013-12-31 아스텍스 테라퓨틱스 리미티드 제약 화합물
CA2596210C (en) 2005-02-03 2014-07-08 Topotarget Uk Limited Combination therapies using hdac inhibitors
US20090036607A1 (en) * 2005-03-03 2009-02-05 Mitsubishi Rayon Co., Ltd. Polymer particle, resin composition containing same, and molded body
US8835501B2 (en) * 2005-05-13 2014-09-16 Topotarget Uk Limited Pharmaceutical formulations of HDAC inhibitors
EP1743890A1 (en) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. 4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments
US7897589B2 (en) 2005-07-15 2011-03-01 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
EP1743892A1 (en) 2005-07-15 2007-01-17 Laboratorios del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
WO2007054719A2 (en) 2005-11-10 2007-05-18 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent
EP2027109A1 (en) * 2006-05-05 2009-02-25 Astex Therapeutics Limited 4- (2, 6-dichloro-benzoylamino) -1h-pyrazole-s-carboxylic acid (1-methanesulph0nyl-piperidin-4-yl) -amide for the treatment of cancer
WO2007129062A1 (en) * 2006-05-08 2007-11-15 Astex Therapeutics Limited Pharmaceutical combinations of diazole derivatives for cancer treatment
US20090263398A1 (en) * 2006-07-14 2009-10-22 Astex Therapeutics Limited Pharmaceutical combinations
JP2009543771A (ja) * 2006-07-14 2009-12-10 アステックス・セラピューティクス・リミテッド 医薬化合物
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
WO2009040517A2 (en) * 2007-09-25 2009-04-02 Topotarget Uk Limited Methods of synthesis of certain hydroxamic acid compounds
EP2070925A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Neue 2-substituierte Tiazol-4-carbonsäureamid-Derivative deren Herstellung und Verwendung als Arzneimittel
EP2070916A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft 2-Aryl-thiazol-4-carbonsäureamid-Derivate, deren Herstellung und Verwendung als Arzneimittel
EP2070924A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Neue 2-Hetarylthiazol-4-carbonsäureamid-Derivative, deren Herstellung und Verwendung als Arzneimittel
CN101945867A (zh) 2007-12-19 2011-01-12 安姆根有限公司 作为细胞周期抑制剂的稠合吡啶、嘧啶和三嗪化合物
WO2009094224A1 (en) 2008-01-25 2009-07-30 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
EP2262493B1 (en) * 2008-03-07 2015-02-25 Topotarget A/S Methods of treatment employing prolonged continuous infusion of belinostat
WO2009126584A1 (en) 2008-04-07 2009-10-15 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
US9560967B2 (en) 2008-04-24 2017-02-07 The Invention Science Fund I Llc Systems and apparatus for measuring a bioactive agent effect
US9662391B2 (en) 2008-04-24 2017-05-30 The Invention Science Fund I Llc Side effect ameliorating combination therapeutic products and systems
US20090270688A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting a combination treatment
US9649469B2 (en) 2008-04-24 2017-05-16 The Invention Science Fund I Llc Methods and systems for presenting a combination treatment
US9282927B2 (en) 2008-04-24 2016-03-15 Invention Science Fund I, Llc Methods and systems for modifying bioactive agent use
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
EP2391619A1 (en) 2009-01-30 2011-12-07 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
HRP20170702T1 (hr) 2009-10-01 2017-07-14 Janssen Pharmaceutica Nv Inhibitori proteazoma za liječenje karcinoma
WO2012021615A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
AR082665A1 (es) 2010-08-11 2012-12-26 Millennium Pharm Inc Derivados heteroarilicos inhibidores de quinasas pi3k, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos proliferativos, inflamatorios y/o cardiovasculares
SG189396A1 (en) 2010-10-13 2013-05-31 Millennium Pharm Inc Heteroaryls and uses thereof
EP2688887B1 (en) 2011-03-23 2015-05-13 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
JP2015503505A (ja) * 2011-12-23 2015-02-02 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヘテロアリールおよびその使用
CN103012428A (zh) 2013-01-08 2013-04-03 中国药科大学 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途
US9682995B2 (en) * 2013-01-30 2017-06-20 Bayer Pharma Aktiengesellschaft Amino-substituted isothiazoles
EP2970133B1 (en) 2013-03-14 2018-10-24 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
CA2903264A1 (en) 2013-03-14 2014-11-06 Epizyme, Inc. Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof
WO2014144659A1 (en) 2013-03-14 2014-09-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
SG11201506972PA (en) 2013-03-14 2015-10-29 Epizyme Inc Arginine methyltransferase inhibitors and uses thereof
US9394258B2 (en) 2013-03-14 2016-07-19 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9133189B2 (en) 2013-03-14 2015-09-15 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9045455B2 (en) 2013-03-14 2015-06-02 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970131B1 (en) 2013-03-14 2017-11-15 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
JP7054622B2 (ja) 2014-07-21 2022-04-14 ノバルティス アーゲー ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置
WO2016044576A1 (en) * 2014-09-17 2016-03-24 Epizyme, Inc. Salts, co-crystals, amorphous forms, and crystalline forms of an arginine methyltransferase inhibitor
WO2018004290A1 (ko) * 2016-06-30 2018-01-04 한미약품 주식회사 Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도
KR102434226B1 (ko) 2016-06-30 2022-08-19 한미약품 주식회사 Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도
ES2966469T3 (es) 2016-08-23 2024-04-22 Eisai R&D Man Co Ltd Terapias combinadas para el tratamiento del carcinoma hepatocelular
IL269357B2 (en) 2017-03-16 2024-10-01 Eisai R&D Man Co Ltd A combination of ER? inhibitor and CDK 4/6 inhibitor for use in a method of treating breast cancer
JP7438988B2 (ja) 2018-06-13 2024-02-27 ノバルティス アーゲー Ｂｃｍａキメラ抗原受容体及びその使用
GB201903546D0 (en) * 2019-03-15 2019-05-01 Ldn Pharma Ltd Cancer treatment

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2917432A (en) 1954-10-05 1959-12-15 Burroughs Wellcome Co Leukemia treatment
US2848455A (en) 1955-07-18 1958-08-19 Ciba Pharm Prod Inc Alpha-(p-amino-phenyl)-alpha-lower alkyl glutarimides
US2891079A (en) 1959-01-23 1959-06-16 Searle & Co 6-methyl-4, 6-pregnadiene-3, 20-dione and 17alpha-acyloxy derivatives thereof
US3046301A (en) 1959-10-29 1962-07-24 Burroughs Wellcome Co Method of making chlorambucil
BE637389A (pt) 1962-09-13
US3732340A (en) 1966-07-11 1973-05-08 Asta Werke Ag Chem Fab N',o-propylene phosphoric acid ester diamides
GB1354939A (en) 1971-10-28 1974-06-05 Ici Ltd Process for the manufacture of 1,1,2-triphenylalk-1-enes
US3914412A (en) 1973-10-11 1975-10-21 Abbott Lab {8 Des{13 Gly{9 {0 10 -Gn{13 RH nonapeptide amide analogs in position 6 having ovulation-inducing activity
US4005063A (en) 1973-10-11 1977-01-25 Abbott Laboratories [Des-gly]10 -GnRH nonapeptide anide analogs in position 6 having ovulation-inducing activity
DE2438350C3 (de) 1974-08-09 1979-06-13 Hoechst Ag, 6000 Frankfurt Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
US4282361A (en) * 1978-03-16 1981-08-04 Massachusetts Institute Of Technology Synthesis for 7-alkylamino-3-methylpyrazolo [4,3-d]pyrimidines
DE2845574A1 (de) 1978-10-19 1980-04-24 Deutsches Krebsforsch Durch heterocyclische ringe oder alkylreste substituierte analoga von ccnu und verfahren zu deren herstellung
DE3046719C2 (de) 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
OA07174A (fr) 1981-08-24 1984-04-30 May & Baker Ltd Nouvelles imidazotétrazionones, leur préparation et les médicaments qui les contiennent.
GB2126576B (en) 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
EP0100172B1 (en) 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5003011A (en) 1985-04-09 1991-03-26 The Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4978672A (en) 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
JPS62220196A (ja) 1986-03-20 1987-09-28 Kyowa Hakko Kogyo Co Ltd 新規物質ｕｃｎ―０１
IN164232B (pt) 1986-04-11 1989-02-04 Hoechst India
NZ224714A (en) 1987-06-01 1990-03-27 Janssen Pharmaceutica Nv Substituted benzotriazole derivatives and pharmaceutical compositions
GB8714013D0 (en) 1987-06-16 1987-07-22 Ici Plc (substituted-aralkyl)heterocyclic compounds
EP0308020A3 (en) 1987-09-18 1990-12-05 Merck & Co. Inc. 5-(aryl and heteroaryl)-6-(aryl and heteroaryl)-1,2-dihydro-2-oxo 3-pyridinecarboxylic acids and derivatives thereof
US5002755A (en) * 1988-02-18 1991-03-26 Vanderbilt University Method of controlling nephrotoxicity of anti-tumor plaintum compounds
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
AU7885991A (en) * 1990-05-26 1991-12-31 Byk Gulden Lomberg Chemische Fabrik Gmbh 1,4-dihydropyridines for application in combatting resistance to drugs
TW295589B (pt) 1990-08-30 1997-01-11 Hoechst Ag
GB9112859D0 (en) 1991-06-14 1991-07-31 Ici Plc Peptide process
PL174494B1 (pl) 1992-11-13 1998-08-31 Idec Pharma Corp Kompozycja farmaceutyczna do leczenia chłoniaka z limfocytów B i sposób wytwarzania kompozycji farmaceutycznej do leczenia chłoniaka z limfocytów B
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
RU2139281C1 (ru) 1993-11-30 1999-10-10 Джи Ди Сирл энд Компани Пиразолилзамещенный бензолсульфонамид или его фармацевтически приемлемая соль, фармацевтическая композиция, способ лечения от воспаления или связанного с воспалением заболевания
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5502068A (en) * 1995-01-31 1996-03-26 Synphar Laboratories, Inc. Cyclopropylpyrroloindole-oligopeptide anticancer agents
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
GB9514380D0 (en) 1995-07-13 1995-09-13 Knoll Ag Therapeutic agents
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
US5882864A (en) 1995-07-31 1999-03-16 Urocor Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US5675024A (en) 1995-11-22 1997-10-07 Allergan Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6066738A (en) * 1996-01-30 2000-05-23 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997040017A2 (en) 1996-04-19 1997-10-30 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
CZ298260B6 (cs) * 1996-05-03 2007-08-08 Abbott Laboratories Antiangiogenní peptidy, zpusob jejich prípravy, polynukleotidy je kódující
AU724541B2 (en) 1996-06-21 2000-09-21 Allergan, Inc. Substituted tetrahydronaphthalene and dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
EP0827742A1 (en) 1996-09-04 1998-03-11 Vrije Universiteit Brussel Use of histone deacetylase inhibitors for treating fribosis or cirrhosis
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
WO1998033798A2 (en) 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
GB9719426D0 (en) 1997-09-13 1997-11-12 Johnson Matthey Plc Novel process
PL342447A1 (en) 1997-10-27 2001-06-04 Agouron Pharma Substituted 4-amino thiazol-2-yl compounds as inhibitors of cyclin-dependent kinases
JP2000186092A (ja) * 1998-12-22 2000-07-04 Kyowa Hakko Kogyo Co Ltd Ｕｃｎ−０１の製造法
EP1140862A4 (en) 1998-12-23 2004-07-28 Bristol Myers Squibb Pharma Co THROMBIN OR Xa FACTOR INHIBITORS
AU4327600A (en) 1999-04-02 2000-10-23 Du Pont Pharmaceuticals Company Aryl sulfonyls as factor xa inhibitors
EP1169038B9 (en) 1999-04-15 2013-07-10 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
FR2795726A1 (fr) 1999-06-30 2001-01-05 Aventis Cropscience Sa Nouveaux pyrazoles fongicides
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
IL148698A0 (en) 1999-09-17 2002-09-12 Cor Therapeutics Inc INHIBITORS OF FACTOR Xa
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
MY125768A (en) 1999-12-15 2006-08-30 Bristol Myers Squibb Co N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
WO2001058869A2 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
ES2254385T3 (es) 2000-02-29 2006-06-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
US20040087798A1 (en) * 2000-03-14 2004-05-06 Akira Yamada Novel amide compounds
WO2001072745A1 (en) 2000-03-29 2001-10-04 Cyclacel Limited 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders
DE60108626T2 (de) 2000-04-25 2005-12-22 Bristol-Myers Squibb Co. Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
US6414013B1 (en) 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
EP1414804A1 (en) 2000-10-20 2004-05-06 Bristol-Myers Squibb Pharma Company Acylsemicarbazides and their use as cyclin dependent kinase (cdk) inhibitors
US6455559B1 (en) 2001-07-19 2002-09-24 Pharmacia Italia S.P.A. Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents
SK9062003A3 (en) 2000-12-22 2004-04-06 Ortho Mcneil Pharm Inc Substituted triazole diamine derivatives as kinase inhibitors
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7105682B2 (en) * 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
JPWO2002074298A1 (ja) * 2001-03-21 2004-07-08 小野薬品工業株式会社 Ｉｌ−６産生阻害剤
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US6989245B2 (en) * 2001-05-11 2006-01-24 The Burnham Institute Screening, diagnostic and therapeutic methods relating to RIZ
MXPA03010810A (es) 2001-05-29 2004-03-22 Schering Ag Pirimidinas inhibidoras de cdk, su obtencion y su uso como medicamentos.
US20030078232A1 (en) 2001-08-08 2003-04-24 Elfatih Elzein Adenosine receptor A3 agonists
AU2002331766A1 (en) 2001-08-31 2003-03-18 University Of Connecticut Novel pyrazole analogs acting on cannabinoid receptors
US6919359B2 (en) 2001-11-08 2005-07-19 Pfizer Inc Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
SE0104462D0 (sv) 2001-12-29 2001-12-29 Carlbiotech Ltd As Peptide purifcation (Peptidrening)
AP1767A (en) * 2002-01-22 2007-08-13 Warner Lambert Co 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones.
EP1487426B1 (en) * 2002-03-04 2012-08-22 Sloan-kettering Institute For Cancer Research Methods of inducing terminal differentiation
US6995168B2 (en) * 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
WO2004000318A2 (en) 2002-06-21 2003-12-31 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
KR20050052500A (ko) * 2002-09-19 2005-06-02 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 이미다조피리딘
WO2004039795A2 (en) 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Amide compounds for the treatment of hyperlipidemia
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US7169797B2 (en) * 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
US7320989B2 (en) * 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
AU2004261459B2 (en) 2003-07-22 2008-06-26 Astex Therapeutics Limited 3, 4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
BRPI0507891A (pt) * 2004-02-20 2007-07-24 Chiron Corp modulação dos processos inflamatório e metastático
WO2005087724A2 (en) * 2004-03-11 2005-09-22 Altana Pharma Ag Sulphonylpyrroles as hdac inhibitors
AR054425A1 (es) * 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
KR101345002B1 (ko) * 2005-01-21 2013-12-31 아스텍스 테라퓨틱스 리미티드 제약 화합물
AR052559A1 (es) * 2005-01-21 2007-03-21 Astex Therapeutics Ltd Derivados de pirazol para inhibir cdk's y gsk's
KR20070107707A (ko) * 2005-01-21 2007-11-07 아스텍스 테라퓨틱스 리미티드 피라졸 키나제 억제제와 추가 항종양제의 조합물
US20080139620A1 (en) * 2005-01-21 2008-06-12 Astex Therapeutics Limited Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's

Also Published As

Publication number Publication date
EP1845973A1 (en) 2007-10-24
WO2006077428A1 (en) 2006-07-27
MX2007008781A (es) 2007-09-11
CA2594477A1 (en) 2006-07-27
JP5475235B2 (ja) 2014-04-16
AU2006207325B2 (en) 2012-08-16
US20090036435A1 (en) 2009-02-05
ES2552338T3 (es) 2015-11-27
CA2594477C (en) 2016-07-12
AU2006207325A1 (en) 2006-07-27
EP1845973B1 (en) 2015-08-12
KR20070107045A (ko) 2007-11-06
KR101346886B1 (ko) 2014-01-02
JP2008528471A (ja) 2008-07-31

Similar Documents

Publication Publication Date Title
BRPI0606455A (pt) compostos farmacêuticos
BRPI0606480A (pt) compostos farmacêuticos
BRPI0606319A2 (pt) compostos farmacêuticos
SE0202465D0 (sv) New compounds
BR0306150A (pt) Composto, uso de um composto, e, composição farmacêutica
DE60204674D1 (de) Retinoid x rezeptormodulatoren
AR005706A1 (es) Inhibidores egfr de 4-aminoquinzolina, procedimiento para su obtencion, composicion farmaceutica que los contiene, uso de los mismos para lapreparacion de un medicamento util como agente antineoplasico
PE20080611A1 (es) Compuestos de azabenzofuranil y metodos de uso
DK1392714T3 (da) Steroider som agonister for FXR
DE60211343D1 (de) Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente
ATE302775T1 (de) Carbolinderivate
CY1110243T1 (el) Ανταγωνιστες npyy5
UA88012C2 (uk) Похідні хіназоліндіону як інгібітори parp
DK1200426T3 (da) Substituerede thien-3-yl-sulfonylamino(thio)carbonyl-tiazolin(thi)oner
ATE496620T1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
DE60222396D1 (de) N-(2-arylethyl) benzylamine als 5-ht6 rezeptor-antagoniste
DE60112306D1 (de) Kondensierte pyrazindionderivate als pde5 inhibitore
ATE346067T1 (de) Carbolinderivate
ATE332903T1 (de) Kondensierte pyridoindolderivate
ATE374190T1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
DE602005027230D1 (de) Cgrp-rezeptorantagonisten
DE60336735D1 (de) Neue biologischaktive molekü le
BRPI0912171A8 (pt) Composto ativador de receptor de glicocorticoide, e, composição
BR0100234A (pt) Compostos de piperidina-4-sulfonamida, processo para a sua preparação e composições farmacêuticas contendo os mesmos
DE60121587D1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]